Amit Rawat1, Ankur Kumar Jindal1, Deepti Suri1, Pandiarajan Vignesh1, Anju Gupta1, Biman Saikia2, Ranjana W Minz2, Aaqib Zaffar Banday1, Rahul Tyagi1, Kanika Arora1, Vibhu Joshi1, Sanjib Mondal1, Jitendra Kumar Shandilya1, Madhubala Sharma1, Mukesh Desai3, Prasad Taur3, Ambreen Pandrowala4, Vijaya Gowri3, Sneha Sawant-Desai5, Maya Gupta5, Aparna Dhondi Dalvi5, Manisha Madkaikar5, Amita Aggarwal6, Revathi Raj7, Ramya Uppuluri7, Sagar Bhattad8, Ananthvikas Jayaram9, Harsha Prasad Lashkari10, Liza Rajasekhar11, Deenadayalan Munirathnam12, Manas Kalra13, Anuj Shukla14, Ruchi Saka1, Rajni Sharma1, Ravinder Garg1, Kohsuke Imai15, Shigeaki Nonoyama16, Osamu Ohara17, Pamela P Lee18, Koon Wing Chan18, Yu-Lung Lau18, Surjit Singh1. 1. Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2. Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 3. Department of Immunology, B. J. Wadia Hospital, Mumbai, India. 4. Bone Marrow Transplant Unit, B. J. Wadia Hospital, Mumbai, India. 5. Department of Pediatric Immunology and Leukocyte Biology, ICMR-National Institute of Immunohematology, K.E.M Hospital, Mumbai, India. 6. Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. 7. Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai, India. 8. Division of Pediatric Immunology and Rheumatology, Department of Pediatrics, Aster CMI Hospital, Bengaluru, India. 9. Neuberg Anand Reference Laboratory, Bengaluru, India. 10. Department of Paediatrics, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India. 11. Department of Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, India. 12. Department of Pediatric Hematology Oncology and Bone Marrow Transplant, Kanchi Kamakoti Childs Trust Hospital, Chennai, India. 13. Department of Pediatric Hematology, Oncology and BMT, Sir Ganga Ram Hospital, New Delhi, India. 14. Niruj Rheumatology Clinic, Ahmedabad, India. 15. Department of Community Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. 16. Department of Pediatrics, National Defense Medical College, Tokorozawa, Japan. 17. Department of Applied Genomics, Kazusa DNA Research Institute, Kisarazu, Japan. 18. Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.
Abstract
Background: There is paucity of literature on XLA from developing countries. Herein we report the clinical and molecular profile and outcome in a multicenter cohort of patients with XLA from India. Methods: Data on XLA from all regional centers supported by the Foundation for Primary Immunodeficiency Diseases (FPID), USA and other institutions providing care to patients with PIDs were collated. Diagnosis of XLA was based on European Society for Immunodeficiencies (ESID) criteria. Results: We received clinical details of 195 patients with a provisional diagnosis of XLA from 12 centers. At final analysis, 145 patients were included (137 'definite XLA' and eight 'probable/possible XLA'). Median age at onset of symptoms was 12.0 (6.0, 36.0) months and median age at diagnosis was 60.0 (31.5, 108) months. Pneumonia was the commonest clinical manifestation (82.6%) followed by otitis media (50%) and diarrhea (42%). Arthritis was seen in 26% patients while 23% patients developed meningitis. Bronchiectasis was seen in 10% and encephalitis (likely viral) in 4.8% patients. Pseudomonas aeruginosa was the commonest bacterial pathogen identified followed by Streptococcus pneumoniae, Staphylococcus aureus and Klebsiella pneumoniae. Molecular analysis revealed 86 variants in 105 unrelated cases. Missense variants in BTK gene were the most common (36%) followed by frameshift (22%) and nonsense variants (21%). Most pathogenic gene variants (53%) were clustered in the distal part of gene encompassing exons 14-19 encoding for the tyrosine kinase domain. Follow-up details were available for 108 patients. Of these, 12% had died till the time of this analysis. The 5-year and 10-year survival was 89.9% and 86.9% respectively. Median duration of follow-up was 61 months and total duration of follow-up was 6083.2 patient-months. All patients received intravenous immunoglobulin (IVIg) replacement therapy. However, in many patients IVIg could not be given at recommended doses or intervals due to difficulties in accessing this therapy because of financial reasons and lack of universal health insurance in India. Hematopoietic stem cell transplant was carried out in four (2.8%) patients. Conclusion: There was a significant delay in the diagnosis and facilities for molecular diagnosis were not available at many centers. Optimal immunoglobulin replacement is still a challenge.
Background: There is paucity of literature on XLA from developing countries. Herein we report the clinical and molecular profile and outcome in a multicenter cohort of patients with XLA from India. Methods: Data on XLA from all regional centers supported by the Foundation for Primary Immunodeficiency Diseases (FPID), USA and other institutions providing care to patients with PIDs were collated. Diagnosis of XLA was based on European Society for Immunodeficiencies (ESID) criteria. Results: We received clinical details of 195 patients with a provisional diagnosis of XLA from 12 centers. At final analysis, 145 patients were included (137 'definite XLA' and eight 'probable/possible XLA'). Median age at onset of symptoms was 12.0 (6.0, 36.0) months and median age at diagnosis was 60.0 (31.5, 108) months. Pneumonia was the commonest clinical manifestation (82.6%) followed by otitis media (50%) and diarrhea (42%). Arthritis was seen in 26% patients while 23% patients developed meningitis. Bronchiectasis was seen in 10% and encephalitis (likely viral) in 4.8% patients. Pseudomonas aeruginosa was the commonest bacterial pathogen identified followed by Streptococcus pneumoniae, Staphylococcus aureus and Klebsiella pneumoniae. Molecular analysis revealed 86 variants in 105 unrelated cases. Missense variants in BTK gene were the most common (36%) followed by frameshift (22%) and nonsense variants (21%). Most pathogenic gene variants (53%) were clustered in the distal part of gene encompassing exons 14-19 encoding for the tyrosine kinase domain. Follow-up details were available for 108 patients. Of these, 12% had died till the time of this analysis. The 5-year and 10-year survival was 89.9% and 86.9% respectively. Median duration of follow-up was 61 months and total duration of follow-up was 6083.2 patient-months. All patients received intravenous immunoglobulin (IVIg) replacement therapy. However, in many patients IVIg could not be given at recommended doses or intervals due to difficulties in accessing this therapy because of financial reasons and lack of universal health insurance in India. Hematopoietic stem cell transplant was carried out in four (2.8%) patients. Conclusion: There was a significant delay in the diagnosis and facilities for molecular diagnosis were not available at many centers. Optimal immunoglobulin replacement is still a challenge.
Authors: Asghar Aghamohammadi; Maurilia Fiorini; Mostafa Moin; Nima Parvaneh; Shahram Teimourian; Mehdi Yeganeh; Francesca Goffi; Hirokazu Kanegane; Ali Akbar Amirzargar; Zahra Pourpak; Nima Rezaei; Ali Salavati; Nima Pouladi; Sina Abdollahzade; Luigi D Notarangelo; Toshio Miyawaki; Alessandro Plebani Journal: Int Arch Allergy Immunol Date: 2006-08-30 Impact factor: 2.749
Authors: Vivian P Hernandez-Trujillo; Chris Scalchunes; Charlotte Cunningham-Rundles; Hans D Ochs; Francisco A Bonilla; Ken Paris; Leman Yel; Kathleen E Sullivan Journal: J Clin Immunol Date: 2014-06-10 Impact factor: 8.317
Authors: S Esenboga; D Cagdas; T T Ozgur; P Gur Cetinkaya; L M Turkdemir; O Sanal; M VanDerBurg; I Tezcan Journal: Scand J Immunol Date: 2018-03 Impact factor: 3.487
Authors: Asghar Aghamohammadi; Hassan Abolhassani; Necil Kutukculer; Steve G Wassilak; Mark A Pallansch; Samantha Kluglein; Jessica Quinn; Roland W Sutter; Xiaochuan Wang; Ozden Sanal; Tatiana Latysheva; Aydan Ikinciogullari; Ewa Bernatowska; Irina A Tuzankina; Beatriz T Costa-Carvalho; Jose Luis Franco; Raz Somech; Elif Karakoc-Aydiner; Surjit Singh; Liliana Bezrodnik; Francisco J Espinosa-Rosales; Anna Shcherbina; Yu-Lung Lau; Shigeaki Nonoyama; Fred Modell; Vicki Modell; Mohamed-Ridha Barbouche; Mark A McKinlay Journal: Front Immunol Date: 2017-06-13 Impact factor: 7.561
Authors: Koon-Wing Chan; Chung-Yin Wong; Daniel Leung; Xingtian Yang; Susanna F S Fok; Priscilla H S Mak; Lei Yao; Wen Ma; Huawei Mao; Xiaodong Zhao; Weiling Liang; Surjit Singh; Mohamed-Ridha Barbouche; Jian-Xin He; Li-Ping Jiang; Woei-Kang Liew; Minh Huong Thi Le; Dina Muktiarti; Fatima Johanna Santos-Ocampo; Reda Djidjik; Brahim Belaid; Intan Hakimah Ismail; Amir Hamzah Abdul Latiff; Way Seah Lee; Tong-Xin Chen; Jinrong Liu; Runming Jin; Xiaochuan Wang; Yin Hsiu Chien; Hsin-Hui Yu; Dinesh Raj; Revathi Raj; Jenifer Vaughan; Michael Urban; Sylvia van den Berg; Brian Eley; Anselm Chi-Wai Lee; Mas Suhaila Isa; Elizabeth Y Ang; Bee Wah Lee; Allen Eng Juh Yeoh; Lynette P Shek; Nguyen Ngoc Quynh Le; Van Anh Thi Nguyen; Anh Phan Nguyen Lien; Regina D Capulong; Joanne Michelle Mallillin; Jose Carlo Miguel M Villanueva; Karol Anne B Camonayan; Michelle De Vera; Roxanne J Casis-Hao; Rommel Crisenio M Lobo; Ruby Foronda; Vicky Wee Eng Binas; Soraya Boushaki; Nadia Kechout; Gun Phongsamart; Siriporn Wongwaree; Chamnanrua Jiratchaya; Mongkol Lao-Araya; Muthita Trakultivakorn; Narissara Suratannon; Orathai Jirapongsananuruk; Teerapol Chantveerawong; Wasu Kamchaisatian; Lee Lee Chan; Mia Tuang Koh; Ke Juin Wong; Siew Moy Fong; Meow-Keong Thong; Zarina Abdul Latiff; Lokman Mohd Noh; Rajiva de Silva; Zineb Jouhadi; Khulood Al-Saad; Pandiarajan Vignesh; Ankur Kumar Jindal; Amit Rawat; Anju Gupta; Deepti Suri; Jing Yang; Elaine Yuen-Ling Au; Janette Siu-Yin Kwok; Siu-Yuen Chan; Wayland Yuk-Fun Hui; Gilbert T Chua; Jaime Rosa Duque; Kai-Ning Cheong; Patrick Chun Yin Chong; Marco Hok Kung Ho; Tsz-Leung Lee; Wilfred Hing-Sang Wong; Wanling Yang; Pamela P Lee; Wenwei Tu; Xi-Qiang Yang; Yu Lung Lau Journal: Front Immunol Date: 2022-07-08 Impact factor: 8.786